Hepatitis C vaccine - Chiron/CSL

Drug Profile

Hepatitis C vaccine - Chiron/CSL

Alternative Names: HCV/ISCOMATRIX

Latest Information Update: 20 Apr 2010

Price : $50

At a glance

  • Originator CSL; Novartis
  • Class Hepatitis C vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 28 Sep 2004 Phase-II clinical trials in Hepatitis C in Australia (unspecified route)
  • 03 Nov 2003 Phase-I clinical trials in Hepatitis C in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top